Literature DB >> 7728953

Thiol and disulfide metabolites of the radiation protector and potential chemopreventive agent WR-2721 are linked to both its anti-cytotoxic and anti-mutagenic mechanisms of action.

D J Grdina1, N Shigematsu, P Dale, G L Newton, J A Aguilera, R C Fahey.   

Abstract

The ability of the potential chemopreventive agent S-2-(3-aminopropylamino)ethylphosphorothioic acid (WR-2721) to protect against radiation-induced mutagenesis at the hprt locus and cell killing was studied using CHO-AA8 cells incubated for 30 min at 37 degrees C in growth medium containing its active thiol 2-[(aminopropyl)amino]ethane-thiol (WR-1065). In parallel experiments, the thiol and disulfide forms of the drug present in cells and incubation medium were determined in order to identify which, if either, of the components were associated with the observed protective effects. Treatment with 4 mM WR-1065 produced significant intracellular levels of the thiol (WRSH) and disulfide (WRSS) forms of the drug, but also caused dramatic elevation of cellular glutathione (GSH) and cysteine levels, accompanied by marked protection against 60Co gamma-photon- and neutron-induced cell killing and mutagenesis. When drug-treated cells were transferred to drug-free medium and incubated for 4 h at 37 degrees C, levels of WRSH and WRSS and protection against cell killing decreased markedly, whereas levels of GSH and cysteine and protection against mutagenesis showed little change. GSH and cysteine levels were not associated with protection against radiation-induced mutagenesis, as established by experiments performed with buthionine sulfoximine to block GSH synthesis. These data do not support the hypothesis that modulation of GSH or cysteine levels by WR-1065 is a major mechanism accounting for protection. Protection against mutagenesis was seen for cells incubated in medium with concentrations of added WR-1065 as low as 10 microM, where cellular levels of WRSH and WRSS became difficult to measure (< or = 5 microM) and no protection against cell killing was found. An unexpected observation was that cells incubated in 40 microM WR-1065 incorporated the drug much more rapidly than expected for uptake by passive diffusion and concentrated the drug to a marked degree; this indicates that a cell-mediated transport system is involved in the uptake of WR-1065 at low drug concentrations.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7728953     DOI: 10.1093/carcin/16.4.767

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  25 in total

1.  The radioprotective agent WR1065 protects cells from radiation damage by regulating the activity of the Tip60 acetyltransferase.

Authors:  Ye Xu; Kalindi Parmar; Fengxia Du; Brendan D Price; Yingli Sun
Journal:  Int J Biochem Mol Biol       Date:  2011-10-20

2.  SOD2-mediated effects induced by WR1065 and low-dose ionizing radiation on micronucleus formation in RKO human colon carcinoma cells.

Authors:  Jeffrey S Murley; Yasushi Kataoka; Richard C Miller; Jian Jian Li; Gayle Woloschak; David J Grdina
Journal:  Radiat Res       Date:  2010-11-08       Impact factor: 2.841

3.  SOD2-mediated adaptive responses induced by low-dose ionizing radiation via TNF signaling and amifostine.

Authors:  J S Murley; K L Baker; R C Miller; T E Darga; R R Weichselbaum; D J Grdina
Journal:  Free Radic Biol Med       Date:  2011-09-03       Impact factor: 7.376

Review 4.  The p53 pathway as a target in cancer therapeutics: obstacles and promise.

Authors:  Anna Mandinova; Sam W Lee
Journal:  Sci Transl Med       Date:  2011-01-05       Impact factor: 17.956

5.  Yeast DEL assay detects protection against radiation-induced cytotoxicity and genotoxicity: adaptation of a microtiter plate version.

Authors:  Kurt Hafer; Yelena Rivina; Robert H Schiestl
Journal:  Radiat Res       Date:  2010-09-20       Impact factor: 2.841

6.  ROS-scavenger and radioprotective efficacy of the new PrC-210 aminothiol.

Authors:  Daniel D Peebles; Cheryl M Soref; Richard R Copp; Allen L Thunberg; William E Fahl
Journal:  Radiat Res       Date:  2012-06-14       Impact factor: 2.841

Review 7.  Clinical and preclinical modulation of chemotherapy-induced toxicity in patients with cancer.

Authors:  K Hoekman; W J van der Vijgh; J B Vermorken
Journal:  Drugs       Date:  1999-02       Impact factor: 9.546

Review 8.  Biological determinants of radioresistance and their remediation in pancreatic cancer.

Authors:  Parthasarathy Seshacharyulu; Michael J Baine; Joshua J Souchek; Melanie Menning; Sukhwinder Kaur; Ying Yan; Michel M Ouellette; Maneesh Jain; Chi Lin; Surinder K Batra
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2017-02-27       Impact factor: 10.680

9.  Delayed radioprotection by nuclear transcription factor kappaB -mediated induction of manganese superoxide dismutase in human microvascular endothelial cells after exposure to the free radical scavenger WR1065.

Authors:  Jeffrey S Murley; Yasushi Kataoka; Christine J Weydert; Larry W Oberley; David J Grdina
Journal:  Free Radic Biol Med       Date:  2005-11-21       Impact factor: 7.376

10.  Antiretroviral activity of the aminothiol WR1065 against Human Immunodeficiency virus (HIV-1) in vitro and Simian Immunodeficiency virus (SIV) ex vivo.

Authors:  Miriam C Poirier; Ofelia A Olivero; Andrew W Hardy; Genoveffa Franchini; Jennifer P Borojerdi; Vernon E Walker; Dale M Walker; Gene M Shearer
Journal:  AIDS Res Ther       Date:  2009-11-06       Impact factor: 2.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.